Multiple Sclerosis Clinical Trial

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

Summary

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study will also assess changes in disease using monitoring techniques including digital biometric device use, biomarker analysis and non-conventional MRI. Select outcomes in the ofatumumab treated group will be compared to a group of Healthy participants to determine if there are similarities between the groups after the patients with MS undergo treatment with ofatumumab.

View Full Description

Full Description

The study is an open-label, multi-center, prospective 18-month study in 118 MS participants with early RRMS (defined as within 6 months of diagnosis of clinically definite RRMS) and who are treatment naïve. It is designed to determine if RRMS participants treated with 20 mg subcutaneous monthly ofatumumab during the earliest part of their disease will benefit from the use of ofatumumab as their first disease modifying therapy. Additionally, RRMS patients will be compared to age- and sex-matched healthy participants (n=50) for select outcomes to observe similarities and differences between the groups.

After giving consent, participants will have a 28-day screening/qualification period. If they qualify to continue, they will start study measures including assessments of clinical and magnetic resonance imaging (MRI) metrics and use of a digital monitoring watch. Additionally, samples will be collected for laboratory and biomarker analysis. RRMS participants will begin treatment with ofatumumab for the next 18 months. Healthy participants will undergo similar assessments; however they will not receive any treatment during the course of the study. Over the 18 months, participants will have regular clinical visits with assessments and sample collection. After 18 months in the trial, participants in both groups will have the option to enter into a 12-month extension (up to 30 months total in study) to collect further information on long-term clinical and MRI outcomes.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:

Signed informed consent must be obtained prior to participation in the study

Age 18-35 years

Patients in the healthy control arm eligible for inclusion must fulfill the following criteria:

Able to obtain MRI (HC with abnormal MRI at Screening will be excluded) and use wearable device

Able to provide blood sample (no CSF will be collected in HC)

Patients in the ofatumumab-treated arm eligible for inclusion must fulfill the following criteria:

Diagnosis of RRMS per McDonald Criteria (2010/2017)
Within 6 months of diagnosis of clinically definite MS (CDMS)
EDSS 0-3.0 (Inclusive)
Treatment-naïve to MS DMT
Able to obtain MRI and attend study visits at sites
Able to use wearable device
Able to provide blood sample (and CSF for sub-group n=15)

Key Exclusion Criteria:

Participants in the healthy control arm meeting any of the following criteria are not eligible for inclusion in this study:

Confounding medical condition as determined by the investigator

RRMS patients fulfilling any of the following exclusion criteria are not eligible for inclusion in this study:

Diseases other than multiple sclerosis responsible for the clinical or MRI presentation
Patients with neuromyelitis optica, Radiologic/ Clinically Isolated Syndrome, Secondary Progressive or Primary Progressive MS diagnosis
Use of experimental or investigational drugs for MS
Previous use of Disease Modifying Therapy (DMT) or chemotherapeutic medications for MS
Relapse between screening and Baseline visits
Known sensitivity to gadolinium; patients with chronic, severe kidney disease
Known history of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes
CNS anomalies that are better accounted for by another disease process or MRI anomalies causing clinically apparent impairments
Known active malignancies
Pregnant or nursing (lactating) women
Females of childbearing potential (all women physiologically capable of becoming pregnant) should use effective contraception while receiving ofatumumab and for 6 months after the last treatment of ofatumumab
Patients with an active chronic disease (or stable but treated with immune therapy) of the immune system other than MS or with immunodeficiency syndrome
Patients with active infections including systemic bacterial, viral (including SARS-CoV-2/COVID-19) or fungal infections, or known to have AIDS or to test positive for HIV antibody at Screening
Patients with neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML), or confirmed PML
Patients with IgG or IgM levels below LLN at Screening
Patients that have received any live or live-attenuated vaccines within 4 weeks prior to first dose of study drug administration
Patients at risk of developing or having reactivation of hepatitis

Study is for people with:

Multiple Sclerosis

Phase:

Phase 4

Estimated Enrollment:

182

Study ID:

NCT05084638

Recruitment Status:

Active, not recruiting

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 36 Locations for this study

See Locations Near You

Novartis Investigative Site
Chandler Arizona, 85226, United States
Novartis Investigative Site
Phoenix Arizona, 85013, United States
Novartis Investigative Site
Phoenix Arizona, 85032, United States
Novartis Investigative Site
Los Angeles California, 90033, United States
Novartis Investigative Site
Torrance California, 90509, United States
Novartis Investigative Site
West Hollywood California, 90048, United States
Novartis Investigative Site
Aurora Colorado, 80045, United States
Novartis Investigative Site
Washington District of Columbia, 20007, United States
Novartis Investigative Site
Altamonte Springs Florida, 32714, United States
Novartis Investigative Site
Boca Raton Florida, 33486, United States
Novartis Investigative Site
Gainesville Florida, 32610, United States
Novartis Investigative Site
Maitland Florida, 32751, United States
Novartis Investigative Site
Orlando Florida, 32806, United States
Novartis Investigative Site
Pensacola Florida, 32514, United States
Novartis Investigative Site
Tallahassee Florida, 32308, United States
Novartis Investigative Site
Tampa Florida, 33612, United States
Novartis Investigative Site
Atlanta Georgia, 30309, United States
Novartis Investigative Site
Jefferson Louisiana, 70121, United States
Novartis Investigative Site
Worcester Massachusetts, 01655, United States
Novartis Investigative Site
Detroit Michigan, 48202, United States
Novartis Investigative Site
Reno Nevada, 89521, United States
Novartis Investigative Site
Hackensack New Jersey, 07601, United States
Novartis Investigative Site
Albuquerque New Mexico, 87131, United States
Novartis Investigative Site
Raleigh North Carolina, 27607, United States
Novartis Investigative Site
Dayton Ohio, 45408, United States
Novartis Investigative Site
Oklahoma City Oklahoma, 73104, United States
Novartis Investigative Site
Philadelphia Pennsylvania, 19107, United States
Novartis Investigative Site
Knoxville Tennessee, 37922, United States
Novartis Investigative Site
Dallas Texas, 75390, United States
Novartis Investigative Site
Houston Texas, 77030, United States
Novartis Investigative Site
San Antonio Texas, 78258, United States
Novartis Investigative Site
Kirkland Washington, 98034, United States
Novartis Investigative Site
Tacoma Washington, 98405, United States
Novartis Investigative Site
Morgantown West Virginia, 26506, United States
Novartis Investigative Site
Milwaukee Wisconsin, 53226, United States
Novartis Investigative Site
Guaynabo , 00968, Puerto Rico

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 4

Estimated Enrollment:

182

Study ID:

NCT05084638

Recruitment Status:

Active, not recruiting

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.